Key result
Doxorubicin chemotherapy is linked to fatal canine cardiomyopathy driven by severe vacuolar degeneration and myocytolysis.
Why the study?
Fatal cardiomyopathy after doxorubicin chemotherapy in dogs is a serious adverse event requiring detailed pathological characterization.
Case Report (n=1)
This case report highlights fatal doxorubicin-induced cardiotoxicity presenting as sudden death and cardiomyopathy in a dog.
Answers are grounded in this paper and cite their sources.
Alerts to fatal doxorubicin cardiomyopathy risk in dogs; leaves open prospective validation of monitoring protocols.
A case is reported of fatal cardiomyopathy in an 8-year-old female German Shepherd after standard chemotherapy with doxorubicin for splenic hemangiosarcoma. The main gross lesion was a moderate bilateral cardiac ventricular dilation with diffusely pale myocardium. Histological analysis revealed severe multifocal vacuolar degeneration of cardiomyocytes, myocytolysis, myofibril loss, myocardial fibrosis, and edema. Myocardial fiber vacuolization and myocytolysis were highly suggestive of doxorubicin cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Banco et al. (2010) conducted a case report in Splenic hemangiosarcoma (n=1). Doxorubicin was evaluated on Fatal cardiomyopathy. Standard doxorubicin chemotherapy in an 8-year-old German Shepherd was associated with fatal cardiomyopathy characterized by severe multifocal vacuolar degeneration and myocytolysis.
Synapse has enriched 10 related papers. Consider them for comparative context: